December 10, 2015 Each year for the past three years, Cure Magazine and Incyte Corporation have recognized efforts within the MPN community with their MPN Hero award. The two categories are commitment to the community or individual. Past winners have included Ruben Mesa, Zhenya Senyak, Joyce Niblack, Richard Silver, and many more. We were honored… Read More »CURE MAGAZINE HONORS MPNRF WITH MPN HERO HONOR
Here is a selection of presentations made during the American Society of Hematology annual meeting. To receive our review of the meeting by MPNRF Scientific Advisory John Crispino make sure to sign up for our free updates here. Gender is a Core Modifier of Disease Outcomes and Survival in the MPN https://ash.confex.com/ash/2015/webprogram/Paper86780.html PRM-151 in Myelofibrosis: Durable Efficacy… Read More »RESEARCH UPDATES FROM ASH 2015
November 17, 2015 According to a paper published in Nature Medicine, the drug MLN8237 (or Alisertib) has reduced tumor cells, blood counts and fibrosis in mouse models of myelofibrosis. Reports John Crispino, PhD, “This new paper shows that Alisertib has an anti-tumor effect in samples of myelofibrosis, similar to what we saw in megakaryocytic leukemia.” … Read More »NATURE MEDICINE: DRUG STOPS REPRODUCTION OF CANCER CELLS IN MYELOFIBROSIS
LEND YOUR VOICE AS MEDICARE ETS STANDARDS FOR MYELOFIBROSIS RELATED STEM CELL TRANSPLANTS On October 29, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule allowing Medicare coverage for stem cell transplants in approved clinical trials for Myelofibrosis (MF) patients. Unfortunately, some of the requirements in the proposed rule would actually decrease… Read More »TAKE ACTION NOW FOR MYELOFIBROSIS
November 6, 2015 Today from the U.K. came the exciting news that an infant with incurable, aggressive leukemia has had her cancer reversed with experimental gene editing. The implications of this first application of gene editing in CAR-T therapy for B-ALL are potentially important for all of us in the MPN community. This is an… Read More »2015 GENE EDITING SUCCESS IN UK WITH INCURABLE LEUKEMIA
To provide clinicians with the most up-to-date and comprehensive treatment recommendations, the National Comprehensive Cancer Network® (NCCN®) today published the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for MPN to specifically outline diagnosis, treatment, and supportive care strategies for Myelofibrosis. Myelofibrosis is a type of MPN that is the result—in most cases—of one of… Read More »NEW NCCN GUIDELINES OUTLINE DIAGNOSIS, TREATMENT STRATEGIES FOR MPNS
September 30, 2015 It’s the last day of September, and we’ve worked hard over the past four weeks plus to raise awareness about the need for research funding and care for people living with Polycythemia Vera, Essential Thrombocythemia and Myelofibrosis. We’ve raised $30,000 during this month, all of which will be put towards ground breaking… Read More »THANK YOU.
Dr. Jennifer Huberty’s research lab, in partnership with the Mayo Clinic and UDAYA Entertainment Inc., is conducting a research study to explore the preliminary effects of a home-based, online-streamed yoga intervention on symptoms and quality of life within Myeloproliferative Neoplasm (MPN) cancer patients. Click here to download the flier. Inclusion Criteria: 1) have a diagnosis of… Read More »YOGA AND MPN
September 23, 2015 CTI BioPharma Corp. today announced their plan to submit a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Pacritinib, an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R. They are requesting approval for this drug as a treatment for patients with intermediate and high-risk… Read More »CTI BIOPHARMA TO SUBMIT NDA FOR PACRITINIB
September 3, 2015 A new study from NEJM (Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia, N Engl J Med 2015; 373:920-928 September 3, 2015) reports that all 18 ET patients in a Phase 2 trial treated with the drug imetelstat exhibited decreased platelet levels, and 16 showed normalized blood cell counts. Eight patients participated… Read More »NEJM REPORTS NORMALIZED BLOOD COUNTS FOR PEOPLE WITH ET ENROLLED IN IMETELSTAT STUDY
